Clinical significance of CCN2/connective tissue growth factor in Behçet's disease patients
- 23 May 2019
- journal article
- research article
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 22 (8) , 1459-1465
Abstract
Aim: Behçet's disease (BD) is a chronic autoimmune vasculitic disorder of unclear pathogenesis. CCN2/CTGF (connective tissue growth factor) is one of the CCN family members which carry out pro‐angiogenic biological functions and play an important role in inflammatory and autoimmune diseases. The aim of the present study was to assess CCN2 plasma concentrations in BD patients and to analyze their association with clinical features of the disease, activity and laboratory parameters.Methods: We included 87 BD patients and 60 healthy control subjects matched for age and gender. Demographic, clinical, disease activity and severity data were recorded. Plasma CCN2 concentrations were measured using enzyme‐linked immunosorbent assay.Results: The plasma concentrations of CCN2 in BD patients were significantly elevated compared to healthy controls. The mean plasma CCN2 levels in patients with major organ involvement were significantly higher than those without. Patients who received steroids or cyclophosphamide showed a significant reduction in CCN2 levels. This was confirmed by the results of multivariate analysis. Patients with active ocular disease had a significant increase in CCN2 compared to the inactive group. On the other hand, CCN2 levels were not significantly correlated with overall disease activity and severity scores.Conclusion: Behçet's disease patients showed a significant increase of CCN2 levels, especially in the group of patients with major organ involvement. A significant reduction of these levels was found in patients who received steroids or cyclophosphamide. Larger studies with further investigations of the precise role of CCN2 in BD pathogenesis might lead to novel therapies for the clinical management of this disease.Keywords
This publication has 28 references indexed in Scilit:
- CCN1 and CCN2: blood brothers in angiogenic actionJournal of Cell Communication and Signaling, 2012
- CCN2/Connective Tissue Growth Factor Is Essential for Pericyte Adhesion and Endothelial Basement Membrane Formation during AngiogenesisPLOS ONE, 2012
- Connective tissue growth factor gene expression and decline in renal function in lupus nephritisExperimental and Therapeutic Medicine, 2012
- Taking aim at the extracellular matrix: CCN proteins as emerging therapeutic targetsNature Reviews Drug Discovery, 2011
- Connective tissue growth factor promotes articular damage by increased osteoclastogenesis in patients with rheumatoid arthritisArthritis Research & Therapy, 2009
- Oxidative stress: Correlation with Behçet's disease duration, activity and severityEuropean Journal of Internal Medicine, 2008
- N-terminal connective tissue growth factor is a marker of the fibrotic phenotype in sclerodermaQJM: An International Journal of Medicine, 2005
- Behçet's disease: infectious aetiology, new autoantigens, and HLA-B51Annals of the Rheumatic Diseases, 2001
- CTGF and SMADs, Maintenance of Scleroderma Phenotype Is Independent of SMAD SignalingJournal of Biological Chemistry, 2001
- Vascular Endothelial Growth Factor Induces Expression of Connective Tissue Growth Factor via KDR, Flt1, and Phosphatidylinositol 3-Kinase-Akt-dependent Pathways in Retinal Vascular CellsJournal of Biological Chemistry, 2000